TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
- Written by PR Newswire
 |
- TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors
- Interim results from an ongoing Phase 1a study in healthy male volunteers will be presented at International Society on Thrombosis...
